Ｌｉｎｅｚｏｌｉｄ耐性Ｅｎｔｅｒｏｃｏｃｃｕｓ ｆａｅｃｉｕｍが検出された難治性後腹膜膿瘍の１症例
スポンサーリンク
概要
- 論文の詳細を見る
The new oxazolidinone antimicrobial, linezolid (LZD), has been approved for the treatment of infections caused by grampositive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Though LZD-resistant strains have been reported in Europe and the United States, none have yet been discovered in Japan. We report the case of a patient with intractable retroperitoneal abscess infected with E. faecium who was initially treated successfully with LZD but E. faecium subsequently exhibited resistance to LZD. The patient was a 66-year-old female in whom most of the E. faecium infection was detected in the retroperitoneum. Neither teicoplanin (TEIC) nor vancomycin (VCM) had any effect so LZD was then administered at a dose of 1,200 mg/day. The subsequent clinical course was good but following withdrawal of LZD, the infection recurred and was aggravated. The administration of LZD was restarted and the patient recovered when it was continued over the long-term. However, during this period E. faecium became LZD-resistant with the resistance stemming from a G2576 T mutation of the 23S rRNA gene, which suggests that long-term administration can be a tolerance-related risk factor and that LZD induces the resistance mechanism at a certain frequency of use. Pharmacists responsible for infection control should therefore conduct sensitivity testing on isolates from the beginning of LZD treatment to monitor for resistance to LZD.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)